Abstract:Head and Neck Squamous Cell Carcinoma (HNSCC) is one of the most common form of cancer worldwide. It has high incidence and mortality rate making it one of the top causes of cancer related deaths. Tremendous efforts have being made towards treatment of HNSCC but still the overall survival rate hasn't improved much. Unregulated activation of Rho GTPase Ras-related C3 botulinum toxin substrate 1 or Rac1 has been reported in various tumor such as HNSCC, breast cancer, pancreatic cancer, etc. Rac1 is significant in activation and regulation of multiple signaling pathways and it's aberrant activation leads to uncontrolled proliferation, invasion and metastasis which contributes to the hallmarks of cancer. Therefore for treating proliferative disorders such as cancer, inhibition of Rac1 could be a viable approach. Rho GTPases were earlier considered "undruggable" due to their picomolar binding affinity for their guanine nucleotides. In addition presence of high micromolar concentrations of GDP (> 30 μm) and GTP (> 300 μm) in the cell, led to unsuccessful attempts in identification of potent or selective nucleotide competitive GTPase inhibitors. Therefore we identified small molecule inhibitors that target the GEF binding site of the Rho GTPase instead of nucleotide binding site by performing high throughput screening, molecular dynamics simulations, free energy calculations and protein-ligand interaction studies. As a result of this study, we identified four potential inhibitors against RAC1. This study provides a significant in-depth understanding of the Rho GTPases and can prove beneficial in the development of potential therapeutics against HNSCC.

Discovery and characterization of small molecules that target the GTPase Ral

Discovery and Characterization of Small Molecules That Target the Ral GTPase

Drugging the Ral GTPase.

Early-stage structure-based drug discovery for small GTPases by NMR spectroscopy

One Step Closer to Targeting RAS.

RAL GTPases: Biology and Potential As Therapeutic Targets in Cancer

Developing Small Molecules that Inhibit K-Ras/GTP Binding Based on New Affinity Measurements

Targeting Ras-, Rho-, and Rab-family GTPases via a conserved cryptic pocket

Reversible Small Molecule pan-Ras Inhibitors Display Tunable Affinity for the Active and Inactive forms of Ras.

In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C

Discovery of small-molecule inhibitors of RUVBL1/2 ATPase

Advances in the Development of Rho GTPase Inhibitors

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Biophysical and Biochemical Characterization of Structurally Diverse Small Molecules Hits for KRAS Inhibition

Validation of a small molecule inhibitor of PDE6D-RAS interaction with favorable anti-leukemic effects

Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling.

Identification of potent and novel inhibitors against RAC1: a Rho family GTPase

Discovery and characterization of small-molecule TGR5 ligands with agonistic activity

Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer

Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment

In Silico Design of Novel RGS2-Galpha-q Interaction Inhibitors with Anticancer Activity